{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:07:49Z","timestamp":1781626069031,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jpba.2015.01.027","type":"journal-article","created":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T14:16:06Z","timestamp":1421763366000},"page":"409-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Multiplexed LC-MS\/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma"],"prefix":"10.1016","volume":"107","author":[{"given":"Hao","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Kandoussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Demers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Eley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Burrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Easter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pathanjali","family":"Kadiyala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Pursley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cojocaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanda","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Fran\u00e7oise","family":"Aubry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2015.01.027_bib0120","doi-asserted-by":"crossref","unstructured":"National institutes of health consensus development conference statement: management of hepatitis C, Hepatology 36 (2002) S3\u201320.","DOI":"10.1002\/hep.1840360703"},{"issue":"Suppl. 1","key":"10.1016\/j.jpba.2015.01.027_bib0125","first-page":"5460","article-title":"Viral heterogeneity of the hepatitis C virus","volume":"31","author":"Simmonds","year":"1999","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jpba.2015.01.027_bib0130","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2015.01.027_bib0135","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jpba.2015.01.027_bib0140","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1128\/AAC.01186-12","article-title":"Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)","volume":"56","author":"McPhee","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2015.01.027_bib0145","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1128\/AAC.02495-13","article-title":"Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase","volume":"58","author":"Lemm","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2015.01.027_bib0150","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1128\/AAC.01209-12","article-title":"Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir","volume":"56","author":"Pelosi","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2015.01.027_bib0155","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1128\/AAC.02164-12","article-title":"Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses","volume":"57","author":"Gottwein","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2015.01.027_bib0160","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/hep.24724","article-title":"Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders","volume":"55","author":"Chayama","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2015.01.027_bib0165","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","article-title":"Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options","volume":"58","author":"Suzuki","year":"2013","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jpba.2015.01.027_bib0170","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jpba.2015.01.027_bib0175","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jpba.2015.01.027_bib0180","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1128\/AAC.02579-13","article-title":"Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection","volume":"58","author":"Sims","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2015.01.027_bib0185","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1016\/j.jchromb.2011.05.036","article-title":"A rugged and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of BMS-790052 in plasma","volume":"879","author":"Jiang","year":"2011","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2015.01.027_bib0190","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.chroma.2012.05.028","article-title":"A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclatasvir) in human plasma and urine","volume":"1245","author":"Jiang","year":"2012","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2015.01.027_bib0195","doi-asserted-by":"crossref","first-page":"10031","DOI":"10.1021\/ac3024558","article-title":"Practical and efficient strategy for evaluating oral absolute bioavailability with an intravenous microdose of a stable isotopically-labeled drug using a selected reaction monitoring mass spectrometry assay","volume":"84","author":"Jiang","year":"2012","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2015.01.027_bib0200","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1021\/ac200820q","article-title":"A convenient strategy for quantitative determination of drug concentrations in tissue homogenates using a liquid chromatography\/tandem mass spectrometry assay for plasma samples","volume":"83","author":"Jiang","year":"2011","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2015.01.027_bib0205","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jchromb.2013.01.029","article-title":"A rugged and accurate liquid chromatography-tandem mass spectrometry method for the determination of asunaprevir, an NS3 protease inhibitor, in plasma","volume":"921","author":"Yuan","year":"2013","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2015.01.027_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchromb.2014.10.005","article-title":"A validated LC-MS\/MS method for the simultaneous determination of BMS-791325, a hepatitis C virus NS5B RNA polymerase inhibitor, and its metabolite in plasma","volume":"973","author":"Yuan","year":"2014","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2015.01.027_bib0215","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpba.2014.12.011","article-title":"Sensitive and accurate liquid chromatography-tandem mass spectrometry methods for quantitative determination of a novel hepatitis C NS5B inhibitor BMS-791325 and its active metabolite in human plasma and urine","volume":"107","author":"Jiang","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2015.01.027_bib0220","unstructured":"Guidance for Industry: Bioanalytical Method Validation, http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070107.pdf."},{"key":"10.1016\/j.jpba.2015.01.027_bib0225","unstructured":"Guideline on bioanalytical method validation, European Medicines Agency, 2011, http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf."},{"key":"10.1016\/j.jpba.2015.01.027_bib0230","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4155\/bio.12.291","article-title":"Fit-for-purpose bioanalytical cross-validation for LC-MS\/MS assays in clinical studies","volume":"5","author":"Xu","year":"2013","journal-title":"Bioanalysis"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708515000370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708515000370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T01:56:34Z","timestamp":1537926994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708515000370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":23,"alternative-id":["S0731708515000370"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2015.01.027","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiplexed LC-MS\/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2015.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}